Rigel's GAVRETO Shows 70% Response in Lung Cancer—Why the Stock Keeps Falling Despite Strong Data

The event is now in the record books. Rigel published the final 42-month data from its ARROW trial for GAVRETO today in the Journal of Clinical Oncology. The results are a clear validation: the drug showed a 70% overall response rate and a median overall survival of 44.3 months in patients with RET fusion-positive non-small cell lung cancer. This is positive, expected news for a drug already on the market. The market's reaction, however, was anything but celebratory.

The stock's immediate price action tells the real story. Despite the data, shares are down 2.9% today and have fallen 25.7% over the past 20 days. They are trading near $25.72, just above the year's low of $15.50. This muted, even negative, reaction suggests the good news was already priced in. The market has moved on to focus on the broader financial and competitive pressures facing the company.

The valuation context underscores the disconnect. With a forward P/E of 3.3 and a market cap of $475 million, the stock is trading at a steep discount. This isn't a valuation based on future growth potential; it's a discount reflecting deep-seated concerns. The catalyst of positive trial data has been absorbed, but the stock's steep decline shows investors are looking past efficacy to the bottom line.

Financial Context: GAVRETO's Role in a Record-Breaking Year

The financial picture for Rigel is one of stark contrast. The company reported record-breaking results for 2025, with total revenues soaring 64% to $294.3 million. Yet this headline growth is almost entirely driven by a single source: its hematology drug, TAVALISSE. The story for GAVRETO, the oncology asset validated by today's data, is more nuanced and highlights the company's financial vulnerability.

GAVRETO's contribution to the top line was modest. The drug generated net product sales of $42.1 million for the full year, accounting for just 18% of the company's total $232.0 million in net product sales. While the sales grew 146% since commercialization began in mid-2024, that year-over-year growth rate of 18% for 2025 pales in comparison to the overall portfolio. The real engine of growth was TAVALISSE, which saw sales climb 52% year-over-year to $158.8 million. This divergence is critical. The company's record revenue growth is being powered by its hematology franchise, not its oncology pipeline.

The bottom line tells a similar story of one-time accounting. Rigel posted a massive net income of $367.0 million for 2025, a huge jump from the prior year. But this figure is heavily inflated by a $245.9 million non-cash deferred income tax benefit. This is not operational profitability; it's a balance sheet adjustment. The underlying business, therefore, is not generating the kind of sustained earnings that would support a premium valuation.

For GAVRETO, this creates a clear setup. The drug is growing, but it's a small part of a much larger story that is being told by TAVALISSE. The stock's poor reaction to today's positive data suggests investors are looking past this single asset's clinical validation to the broader financial reality: Rigel's revenue and profit are not yet driven by its oncology pipeline. The catalyst of strong trial data does not change the fundamental financial context.

Valuation and Forward Scenarios: Is the Stock a Bargain or a Value Trap?

The market's verdict is clear: today's positive data is not enough to justify a higher price. The stock's steep decline suggests investors see a value trap, not a bargain. The setup now hinges on whether the modest growth from GAVRETO can eventually support a more reasonable valuation, or if the company's financial reality will continue to weigh it down.

The primary constraint on GAVRETO's upside is its market niche. The drug is approved for a rare genetic subset of non-small cell lung cancer, with RET fusions present in approximately 1% to 2% of people with NSCLC. This small patient pool, coupled with the necessity for specific biomarker testing, caps the drug's total addressable market. For all its clinical promise, GAVRETO's growth is inherently limited by biology and diagnostic requirements.

This constraint is reflected in the company's own guidance. For 2026, Rigel anticipates total revenues of $275 to $290 million. Given that GAVRETO's 2025 sales were $42.1 million, this implies a growth rate of roughly 10% to 15% for the oncology asset alone. That is a modest pace for a commercial-stage drug, especially one with such a validated profile. The revenue outlook is not a growth story; it's a maintenance and incremental expansion narrative.

The justification for the stock's low valuation is straightforward. With a forward P/E of just 3.3 and a market cap of $475 million, the market is pricing in a company that is still dependent on a single oncology asset for its future. The record-breaking 2025 revenues were driven overwhelmingly by TAVALISSE, not GAVRETO. The stock's discount reflects the need for future pipeline catalysts beyond this one drug. The company's 2026 guidance includes advancing its R289 program, but that remains years away from commercial contribution.

The bottom line is one of high risk and limited near-term reward. The catalyst of strong trial data has been absorbed, and the stock's poor reaction confirms that investors are focused on the financial math. GAVRETO's growth is constrained, its contribution to the top line remains small, and the company's valuation is pinned to a future that is not yet in sight. For now, the event-driven opportunity is not in buying the data, but in watching whether the company can execute on its pipeline to eventually change the story.

Catalysts and Risks: What to Watch Next

The stock's depressed price creates a clear event-driven setup. The immediate catalyst of positive trial data has been absorbed, leaving investors to weigh the financial reality. The next few quarters will determine if this is a temporary mispricing or a reflection of fundamental issues.

The near-term focus is on execution for GAVRETO. The drug's modest growth is constrained by its small patient pool, but market access and payer coverage can accelerate uptake. Investors should watch for updates on reimbursement and formulary positioning, as these can directly impact sales velocity. More importantly, the upcoming data from the TAPISTRY study for a new indication will be a key test. Positive results could expand the drug's addressable market and provide a new growth vector, directly challenging the narrative of limited upside.

The primary risk, however, remains the financial model. GAVRETO's contribution to the top line is still small, and the company's financial health is overly reliant on its hematology franchise. The record 2025 revenue growth was driven overwhelmingly by TAVALISSE, not GAVRETO. If GAVRETO's growth remains slow, the stock's valuation will continue to be pinned to a future that is not yet in sight. The company's 2026 revenue guidance of $275 to $290 million implies only a 10% to 15% increase for the oncology asset, a pace that offers little support for a premium valuation.

This makes any pipeline progress or strategic move critical. The R289 program, with a recommended Phase 2 dose expected in the second half of 2026, is the next major catalyst. Positive data from its Phase 1b study in lower-risk MDS could shift the narrative toward future growth. Yet, with a market cap of just $475 million and a forward P/E of 3.3, the stock offers little margin for error. The current valuation prices in a high probability of failure for these future catalysts. For now, the event-driven opportunity is not in buying the data, but in watching whether the company can execute on its pipeline to eventually change the story.